LESLIE DVORAK: Open Payments
NPI 1265422562 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$39,037 in 117 payments from 16 companies in 2025. Trend: 2023 $3,608 · 2024 $13,663 · 2025 $39,037
Speaker / faculty: $22,858Travel & lodging: $9,128Speaker / faculty: $4,362Food & beverage: $2,689
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 74 | $33,616 |
| Organon LLC | 9 | $4,380 |
| ABBVIE INC. | 8 | $361 |
| ViiV Healthcare Company | 6 | $211 |
| Noven Therapeutics, LLC | 1 | $121 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $95 |
| Axsome Therapeutics, Inc. | 3 | $55 |
| Vanda Pharmaceuticals Inc. | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Janssen Pharmaceuticals, Inc | 1 | $23 |
Products named: Descovy, Yeztugo, NEXPLANON, Biktarvy, VRAYLAR, APRETUDE, Xelstrym, CAPLYTA.
Industry payments across NE — which companies pay providers there.
